Jinglan Pei

1.7k total citations
44 papers, 699 citations indexed

About

Jinglan Pei is a scholar working on Rheumatology, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Jinglan Pei has authored 44 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 17 papers in Pathology and Forensic Medicine and 11 papers in Neurology. Recurrent topics in Jinglan Pei's work include Rheumatoid Arthritis Research and Therapies (22 papers), Multiple Sclerosis Research Studies (15 papers) and Systemic Lupus Erythematosus Research (12 papers). Jinglan Pei is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Multiple Sclerosis Research Studies (15 papers) and Systemic Lupus Erythematosus Research (12 papers). Jinglan Pei collaborates with scholars based in United States, Switzerland and United Kingdom. Jinglan Pei's co-authors include Margaret Michalska, Lisa K. Jennings, Diane Joseph‐McCarthy, Richard C. Becker, Kenneth W. Mahaffey, David J. Moliterno, Robert A. Harrington, Alan Niederman, Enrico P. Veltri and Karen S. Pieper and has published in prestigious journals such as The Lancet, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Jinglan Pei

40 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jinglan Pei United States	14	276	228	199	128	116	44	699
Lone Hvitfeldt Poulsen Denmark	16	192 0.7×	41 0.2×	623 3.1×	96 0.8×	128 1.1×	41	960
Anna E. Schorer United States	12	143 0.5×	96 0.4×	180 0.9×	46 0.4×	112 1.0×	22	621
Krzysztof Chojnowski Poland	15	73 0.3×	55 0.2×	356 1.8×	116 0.9×	76 0.7×	73	704
Mária Škereňová Slovakia	14	59 0.2×	85 0.4×	147 0.7×	60 0.5×	111 1.0×	50	457
D. J. Meiklejohn United Kingdom	9	77 0.3×	82 0.4×	132 0.7×	83 0.6×	25 0.2×	15	437
Anna Södergren Sweden	12	588 2.1×	182 0.8×	94 0.5×	46 0.4×	143 1.2×	33	794
Claire Barro France	12	64 0.2×	85 0.4×	195 1.0×	21 0.2×	38 0.3×	29	601
Yeon S. Ahn United States	9	35 0.1×	58 0.3×	239 1.2×	40 0.3×	157 1.4×	10	488
Silvia Vettore Italy	17	21 0.1×	114 0.5×	475 2.4×	39 0.3×	48 0.4×	39	719
Torgny Smedby Sweden	5	426 1.5×	112 0.5×	69 0.3×	37 0.3×	94 0.8×	6	537

Countries citing papers authored by Jinglan Pei

Since Specialization

Citations

This map shows the geographic impact of Jinglan Pei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinglan Pei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinglan Pei more than expected).

Fields of papers citing papers by Jinglan Pei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinglan Pei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinglan Pei. The network helps show where Jinglan Pei may publish in the future.

Co-authorship network of co-authors of Jinglan Pei

This figure shows the co-authorship network connecting the top 25 collaborators of Jinglan Pei. A scholar is included among the top collaborators of Jinglan Pei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinglan Pei. Jinglan Pei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benedict, Ralph H. B., Ludwig Kappos, Aaron Miller, et al.. (2025). Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials. Multiple Sclerosis and Related Disorders. 95. 106310–106310. 1 indexed citations

Kister, Ilya, Amanda L. Piquet, Jinglan Pei, et al.. (2024). Longitudinal study of immunity toSARS‐CoV2in ocrelizumab‐treatedMSpatients up to 2 years afterCOVID‐19 vaccination. Annals of Clinical and Translational Neurology. 11(7). 1750–1764. 2 indexed citations

Williams, Mitzi, Anne H. Cross, Nancy Monson, et al.. (2023). Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Multiple Sclerosis and Related Disorders. 76. 104794–104794. 8 indexed citations

Zivadinov, Robert, Jinglan Pei, David Clayton, et al.. (2023). Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study. Journal of Neurology Neurosurgery & Psychiatry. 95(6). 536–543. 2 indexed citations

Simpson, Haley, Stefan Sillau, Ryan C. Winger, et al.. (2023). Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis. Annals of Clinical and Translational Neurology. 10(4). 579–588. 4 indexed citations

Amezcua, Lilyana, Anne H. Cross, Nancy Monson, et al.. (2022). Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the CHIMES Trial (P4-4.005). Neurology. 98(18_supplement). 1 indexed citations

Longbrake, Erin E., Le H. Hua, Ellen M. Mowry, et al.. (2022). The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders. 68. 104143–104143. 9 indexed citations

Zivadinov, Robert, Jinglan Pei, David Clayton, et al.. (2021). Evolution of Lesions that Shrink or Disappear into Cerebrospinal Fluid (Atrophied T2 Lesion Volume) in Primary-Progressive Multiple Sclerosis: Results from the Phase III ORATORIO Study (107). Neurology. 96(15_supplement). 1 indexed citations

Cree, Bruce, Ashish Pradhan, Jinglan Pei, & Mitzi Williams. (2021). Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders. 52. 103010–103010. 13 indexed citations

10.

Vollmer, Timothy, Jeffrey A. Cohen, Enrique Álvarez, et al.. (2020). Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 46. 102454–102454. 15 indexed citations

11.

McCulley, Timothy J., Jinglan Pei, Páris Sidiropoulos, et al.. (2019). Visual impairment in patients with giant cell arteritis treated with tocilizumab in real-world clinical practice. Investigative Ophthalmology & Visual Science. 60(9). 242–242. 1 indexed citations

12.

Peterfy, Charles, Joel M. Kremer, William F. C. Rigby, et al.. (2019). Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy. The Journal of Rheumatology. 47(3). 325–332. 2 indexed citations

13.

Gale, Sara, Katie Tuckwell, Neil Collinson, et al.. (2019). Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data. Rheumatology and Therapy. 6(1). 77–88. 22 indexed citations

14.

Xu, Yongfeng, Jie Han, Jinglan Pei, et al.. (2018). PND7 - AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY. Value in Health. 21. S330–S330. 1 indexed citations

15.

Kivitz, Alan, Ewa Olech, Michael Borofsky, et al.. (2017). Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. The Journal of Rheumatology. 45(4). 456–464. 15 indexed citations

16.

Burmester, Gerd R, Ernest Choy, Alan Kivitz, et al.. (2016). Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 76(6). 1078–1085. 82 indexed citations

17.

Kivitz, Alan, Thomas W. Wallace, Ewa Olech, et al.. (2016). Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. Rheumatology and Therapy. 3(2). 291–304. 19 indexed citations

18.

Soubrier, Martin, Jinglan Pei, Frédérick Durand, Lars Gullestad, & Ani John. (2016). Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy. 4(1). 133–149. 29 indexed citations

19.

Becker, Richard C., David J. Moliterno, Lisa K. Jennings, et al.. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. The Lancet. 373(9667). 919–928. 222 indexed citations

20.

Pei, Jinglan, et al.. (2002). Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness. Advances in Space Research. 30(4). 751–755. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact